MX388998B - Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos. - Google Patents
Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos.Info
- Publication number
- MX388998B MX388998B MX2020005952A MX2020005952A MX388998B MX 388998 B MX388998 B MX 388998B MX 2020005952 A MX2020005952 A MX 2020005952A MX 2020005952 A MX2020005952 A MX 2020005952A MX 388998 B MX388998 B MX 388998B
- Authority
- MX
- Mexico
- Prior art keywords
- patient
- microrna
- mir128
- mir101
- seizure disorder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0047—Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762595255P | 2017-12-06 | 2017-12-06 | |
| PCT/US2018/064158 WO2019113266A1 (en) | 2017-12-06 | 2018-12-06 | Use of mir101 or mir128 in the treatment of seizure disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2020005952A MX2020005952A (es) | 2022-01-03 |
| MX388998B true MX388998B (es) | 2025-03-11 |
Family
ID=66658874
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020005952A MX388998B (es) | 2017-12-06 | 2018-12-06 | Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos. |
| MX2021011598A MX2021011598A (es) | 2017-12-06 | 2020-07-13 | Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021011598A MX2021011598A (es) | 2017-12-06 | 2020-07-13 | Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10870855B2 (https=) |
| EP (1) | EP3703820A4 (https=) |
| JP (1) | JP2021505619A (https=) |
| KR (1) | KR20200119782A (https=) |
| CN (1) | CN111417397A (https=) |
| AU (1) | AU2018378622A1 (https=) |
| CA (1) | CA3084985A1 (https=) |
| IL (1) | IL274838A (https=) |
| MX (2) | MX388998B (https=) |
| WO (1) | WO2019113266A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3084985A1 (en) | 2017-12-06 | 2019-06-13 | Ovid Therapeutics Inc. | Use of mir101 or mir128 in the treatment of seizure disorders |
| BR112022002794A2 (pt) * | 2019-08-15 | 2022-08-09 | Childrens Hospital Philadelphia | Terapia combinada de transgene e mirna derivado de íntron para tratamento de sca1 |
| WO2025164317A1 (ja) * | 2024-01-31 | 2025-08-07 | 国立大学法人群馬大学 | 改良型ミクログリア標的aavベクター |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3499437A (en) | 1967-03-10 | 1970-03-10 | Ultrasonic Systems | Method and apparatus for treatment of organic structures and systems thereof with ultrasonic energy |
| US4303636A (en) | 1974-08-20 | 1981-12-01 | Gordon Robert T | Cancer treatment |
| US4315514A (en) | 1980-05-08 | 1982-02-16 | William Drewes | Method and apparatus for selective cell destruction |
| US4923437A (en) | 1986-07-18 | 1990-05-08 | Gordon Robert T | Process for applying a localized magnetic or electric field |
| US5059415A (en) | 1989-02-21 | 1991-10-22 | The State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon Health | Method for diagnostically imaging lesions in the brain inside a blood-brain barrier |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| US5438989A (en) | 1990-08-10 | 1995-08-08 | Hochman; Darryl | Solid tumor, cortical function, and nerve tissue imaging methods and device |
| US5465718A (en) | 1990-08-10 | 1995-11-14 | Hochman; Daryl | Solid tumor, cortical function, and nerve tissue imaging methods and device |
| DE4227800C2 (de) | 1991-08-21 | 1996-12-19 | Toshiba Kawasaki Kk | Thrombuslösende Behandlungsvorrichtung |
| US5291890A (en) | 1991-08-29 | 1994-03-08 | General Electric Company | Magnetic resonance surgery using heat waves produced with focussed ultrasound |
| US5524620A (en) | 1991-11-12 | 1996-06-11 | November Technologies Ltd. | Ablation of blood thrombi by means of acoustic energy |
| JP3325300B2 (ja) | 1992-02-28 | 2002-09-17 | 株式会社東芝 | 超音波治療装置 |
| US5368032A (en) | 1993-11-09 | 1994-11-29 | General Electric Company | Manually positioned focussed energy system guided by medical imaging |
| US5526814A (en) | 1993-11-09 | 1996-06-18 | General Electric Company | Automatically positioned focussed energy system guided by medical imaging |
| US5443068A (en) | 1994-09-26 | 1995-08-22 | General Electric Company | Mechanical positioner for magnetic resonance guided ultrasound therapy |
| US5752515A (en) | 1996-08-21 | 1998-05-19 | Brigham & Women's Hospital | Methods and apparatus for image-guided ultrasound delivery of compounds through the blood-brain barrier |
| EP1937151A4 (en) | 2005-09-19 | 2011-07-06 | Univ Columbia | Systems and methods for opening of the blood-brain barrier of a subject using ultrasound |
| EP2068925A4 (en) * | 2007-05-07 | 2011-08-31 | Medimmune Llc | ANTI-ICOS ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER, TRANSPLANTATIONS AND AUTOIMMUNE DISEASES |
| US9163261B2 (en) * | 2010-02-22 | 2015-10-20 | Koteswara Rao KOLLIPARA | Adeno-associated virus 2/8—micro RNA-101 therapy for liver cancer |
| GB201103062D0 (en) * | 2011-02-22 | 2011-04-06 | Isis Innovation | Method |
| GB201223244D0 (en) * | 2012-12-21 | 2013-02-06 | Ucb Pharma Gmbh | Micrornas as therapeutics and biomarkers for epilepsy |
| CN107207597A (zh) * | 2014-11-06 | 2017-09-26 | 儿研所儿童医学中心 | 用于癌症和自身免疫疾病的免疫疗法 |
| TN2017000354A1 (en) * | 2015-02-10 | 2019-01-16 | Genzyme Corp | VARIANT RNAi |
| WO2017024111A1 (en) * | 2015-08-04 | 2017-02-09 | The University Of Chicago | Inhibitors of cacna1a/alpha1a subunit internal ribosomal entry site (ires) and methods of treating spinocerebellar ataxia type 6 |
| EP3413925A1 (en) * | 2016-02-12 | 2018-12-19 | Combigene AB | Vector |
| CA3056410A1 (en) * | 2017-03-15 | 2018-09-20 | Ovid Therapeutics, Inc. | Use of designer receptors exclusively activated by designer drugs in the treatment of seizure disorders |
| CA3084985A1 (en) | 2017-12-06 | 2019-06-13 | Ovid Therapeutics Inc. | Use of mir101 or mir128 in the treatment of seizure disorders |
-
2018
- 2018-12-06 CA CA3084985A patent/CA3084985A1/en active Pending
- 2018-12-06 WO PCT/US2018/064158 patent/WO2019113266A1/en not_active Ceased
- 2018-12-06 US US16/211,309 patent/US10870855B2/en active Active
- 2018-12-06 JP JP2020531161A patent/JP2021505619A/ja active Pending
- 2018-12-06 KR KR1020207019430A patent/KR20200119782A/ko not_active Withdrawn
- 2018-12-06 EP EP18886725.3A patent/EP3703820A4/en not_active Withdrawn
- 2018-12-06 AU AU2018378622A patent/AU2018378622A1/en not_active Abandoned
- 2018-12-06 MX MX2020005952A patent/MX388998B/es unknown
- 2018-12-06 CN CN201880076488.2A patent/CN111417397A/zh active Pending
-
2020
- 2020-05-21 IL IL274838A patent/IL274838A/en unknown
- 2020-07-13 MX MX2021011598A patent/MX2021011598A/es unknown
- 2020-11-17 US US16/950,395 patent/US11761006B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019113266A1 (en) | 2019-06-13 |
| CA3084985A1 (en) | 2019-06-13 |
| MX2020005952A (es) | 2022-01-03 |
| EP3703820A1 (en) | 2020-09-09 |
| AU2018378622A1 (en) | 2020-05-28 |
| JP2021505619A (ja) | 2021-02-18 |
| US20210095292A1 (en) | 2021-04-01 |
| US20190169619A1 (en) | 2019-06-06 |
| US10870855B2 (en) | 2020-12-22 |
| EP3703820A4 (en) | 2020-12-09 |
| MX2021011598A (es) | 2021-10-13 |
| IL274838A (en) | 2020-07-30 |
| CN111417397A (zh) | 2020-07-14 |
| KR20200119782A (ko) | 2020-10-20 |
| US11761006B2 (en) | 2023-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2017000097A (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
| MX2015013948A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| MX2023000796A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| EA201991650A1 (ru) | Способы лечения неврологических расстройств | |
| DOP2017000025A (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
| EA202092225A1 (ru) | Соединения и их применение | |
| PH12017502103A1 (en) | Methods and kits for treating depression | |
| EA201790195A1 (ru) | Способы лечения рака с применением ингибиторов tigit и противораковых агентов | |
| MX379318B (es) | Metodos para tratar trastornos de sueño de ritmo circadiano. | |
| MX386613B (es) | El uso de un péptido timosina alfa y un inhibidor de pd-1 para el tratamiento de cáncer o una metástasis de este en un sujeto. | |
| JOP20210050A1 (ar) | معدلات تعبير pnpla3 | |
| UA117096C2 (uk) | Поліпептид, що зв'язується з c5 комплементу людини | |
| EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
| BR112017018964A2 (pt) | uso de plinabulin e métodos para tratar tumor cerebral | |
| MX2019010982A (es) | Uso de receptores de diseño activados exclusivamente mediante fármacos de diseño en el tratamiento de trastornos convulsivos. | |
| MX2021013354A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
| EP4285993A3 (en) | Growth differentiation factor 15 as biomarker for metformin | |
| BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
| MX388998B (es) | Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos. | |
| MX2019013716A (es) | Métodos de tratamiento para la distonía cervical. | |
| MX382044B (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés. | |
| JOP20210009A1 (ar) | طرق لعلاج HFpEF باستعمال داباجليفلوزين وتركيبات تشمله | |
| MX2018002298A (es) | Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos. | |
| MX2019013207A (es) | Metodos y composiciones para tratar la endometriosis y sintomas asociados a la endometriosis. |